The invention in this patent application relates to macrocyclic benzimidazole derivatives represented herein generally by Formula 1. The compounds of Formula 1 are cGAS inhibitors and may potentially provide treatments of autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonopathies, and others.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11403758 | PMC |
| http://dx.doi.org/10.1021/acsmedchemlett.4c00392 | DOI Listing |
Publication Analysis
Top Keywords
inhibitors cyclic
4
cyclic gmp-amp
4
gmp-amp synthase
4
synthase cgas
4
cgas potential
4
potential treatment
4
treatment autoimmune
4
autoimmune inflammatory
4
inflammatory diseases
4
diseases patent
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!